Votre parcours clé en main

Polyarthrite rhumatoïde – Pr Philippe Dieudé (Paris)

Spondyloarthrite – Pr Pascal Claudepierre (Créteil)

Maladies auto-immunes – Pr Christophe Richez (Bordeaux)

Le parcours d’or (12-13-14-15 juin)
Nouveaux traitements

- **LB0001 Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results** – Bernard Combe
  - Mercredi 12 juin
  - 16 h 25 – Hall 6 – “Opening plenary abstract session”

- **OP0025 Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: phase 2 study** – Stanley Cohen et al.
  - Mercredi 12 juin
  - 16 h 35 – Hall 8 – Abstract session “RA therapy – JAK inhibitors and beyond”

- **OP0030 Randomized controlled 24-week trial evaluating the safety and efficacy of blinded tapering versus continuation of long-term prednisone (5 mg/d) in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab** – Gerd Rüdiger Burmester et al.
  - Mercredi 12 juin
  - 17 h 25 – Hall 8 – Abstract session “RA therapy – JAK inhibitors and beyond”

- **OP0223 Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in MTX-IR patients with rheumatoid arthritis** – Yoshija Tanaka et al.
  - Vendredi 14 juin
  - 10 h 20 – Hall 8 – Abstract session “Rheumatoid arthritis – Biological DMARDs”

- **OP0224 Results of a phase 2 study of RG6125, an anti-cadherin-11 monoclonal antibody, in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy** – Uwe Junker et al.
  - Vendredi 14 juin
  - 10 h 30 – Hall 8 – Abstract session “Rheumatoid arthritis – Biological DMARDs”

- **OP0228 GSK3196165 an investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis (RA)** – Chris Buckley et al.
  - Vendredi 14 juin
  - 11 h 10 – Hall 8 – Abstract session “Rheumatoid arthritis – Biological DMARDs”

Comorbidités et complications

- **OP0095 Influence of periodontitis on disease activity, physical function, and safety in patients with rheumatoid arthritis: an observational study using the IORRA cohort** – Ryoko Sakai et al.
  - Mercredi 12 juin
  - 17 h 30 – Salle N107/N108 – Abstract session “When rheumatoid arthritis (RA) does not walk alone: new data on comorbidities in RA”

- **Interstitial lung disease and best management in rheumatic disease** – J.C. Grutters
  - Jeudi 13 juin
  - 15 h 35 – Hall 6 – WIN & HOT session “Interstitial lung disease in rheumatic diseases and systemic sclerosis”
Nouvelles stratégies thérapeutiques

- **OP0119 The pre-treatment gut microbiome predicts early response to rheumatoid arthritis therapy** – Carles Ubeda et al.
  - Jeudi 13 juin
  - 10 h 50 – Hall 7A – Abstract session “Rheumatoid arthritis – Looking before, looking forward!”

  - Samedi 15 juin
  - 8 h 06 – Hall 7B – “Late breaking abstracts session”

- **LB0009 First-in-human study of novel implanted vagus nerve stimulation device to treat rheumatoid arthritis** – Mark C. Genovese et al.
  - Samedi 15 juin
  - 8 h 36 – Hall 7B – “Late breaking abstracts session”

  - Samedi 15 juin
  - 8 h 42 – Hall 7B – “Late breaking abstracts session”

- **OP0345 Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved a sustained DMARD-free status** – Debbie Boeters et al.
  - Samedi 15 juin
  - 13 h 05 – Salle N101/N102 – Clinical science session
  - “How low should you go? What is the relevant target in T2T in rheumatoid arthritis?”
**Spondyloarthrite**
— La sélection du Pr Pascal Claudepierre (Créteil)

**Rhumatisme psoriasique**

**Rhumatisme psoriasique et cancer**

- **OP0005** Incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries – René Cordtz et al.
  - Mercredi 12 juin
  - 14 h 51 – Salle N103/N104 – Clinical science session "Comorbidities in psoriatic arthritis"

**Rhumatisme psoriasique et obésité/activité**

- **OP0007** High body mass index (BMI) in psoriatic arthritis (PsA) is associated with higher disease activity in joints and skin, impaired quality of life and more disability: results from the PsAbio study – Stefan Siebert et al.
  - Mercredi 12 juin
  - 15 h 15 – Salle N103/N104 – Clinical science session "Comorbidities in psoriatic arthritis"

**Rhumatisme psoriasique et régime LDA**

- **OP0008** Sustained low disease activity after weight loss treatment in patients with psoriatic arthritis and obesity; a 12-months follow-up – Eva Klingberg et al.
  - Mercredi 12 juin
  - 15 h 27 – Salle N103/N104 – Clinical science session "Comorbidities in psoriatic arthritis"

**Rhumatisme psoriasique et nouvel anti-IL-23**

- **LB0002** Randomised, double-blind, placebo-controlled, multiple-dose, phase 2B study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23P19 monoclonal antibody, in patients with active psoriatic arthritis – Philip J. Mease et al.
  - Mercredi 12 juin
  - 17 h 35 – Hall 6 – "Opening plenary abstract session"

**Rhumatisme psoriasique et anti-IL-17A et A/F**

- **OP0108** Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active PsA: overall and TNF-inhibitor-naïve population results from a 48-week phase 2B randomised study – Christopher T. Ritchlin et al.
  - Jeudi 13 juin
  - 10 h 20 – Hall 8 – Abstract session "Psoriatic arthritis: old and new drugs and how to deal with them?"

- **OP0110** Ixekizumab improves signs and symptoms of psoriatic arthritis in patients who have had inadequate response to 1 or 2 tumor necrosis factor inhibitors – L. Bruce Kirkham et al.
  - Jeudi 13 juin
  - 10 h 40 – Hall 8 – Abstract session "Psoriatic arthritis: old and new drugs and how to deal with them?"

**Rhumatisme psoriasique : un autre inhibiteur de JAK**

- **OP0109** Efficacy of filgotinib vs placebo in active psoriatic arthritis: patient-level data from equator, a randomized, phase 2 study – Philip J. Mease et al.
  - Jeudi 13 juin
  - 10 h 30 – Hall 8 – Abstract session "Psoriatic arthritis: old and new drugs and how to deal with them?"

**Rhumatisme psoriasique : monothérapie versus combothérapie**

- **OP0111** A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combination for treating psoriatic arthritis: a comparison of the composite measures used to evaluate disease activity – Philip J. Mease et al.
  - Jeudi 13 juin
  - 10 h 50 – Hall 8 – Abstract session "Psoriatic arthritis: old and new drugs and how to deal with them?"

**Rhumatisme psoriasique et facteurs prédictifs de spondyloarthrite**

- **OP0115** General and sex-specific predictors of PsA among patients with psoriasis – Alexis Ogdie et al.
  - Jeudi 13 juin
  - 11 h 30 – Hall 8 – Abstract session "Psoriatic arthritis: old and new drugs and how to deal with them?"
Spondyloarthrite axiale

Environnement et structural

- OP0034 Do smoking and socio-economic factors independently influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort – Elena Nikiphorou et al.
  - Mercredi 12 juin
  - 16 h 45 – Hall 7A – Abstract session “Spondyloarthritis on the move: thrilling developments”

Face-face ixekizumab/adalimumab

- LB0005 Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week results – Philip J. Mease et al.
  - Samedi 15 juin
  - 8 h 12 – Hall 7B – “Late breaking abstracts session”

Anti-IL-17 A/F et nouvel anti-IL-17

- OP0231 Dual neutralisation of IL-17A and IL-17F with bimekizumab was associated with improvements in patient-reported and quality-of-life outcomes in patients with active ankylosing spondylitis: results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study – Désirée van der Heijde et al.
  - Vendredi 14 juin
  - 10 h 20 – Hall 7A – Abstract session “How to treat SpA: choices and outcomes with bDMARDs”

  - Vendredi 14 juin
  - 10 h 40 – Hall 7A – Abstract session “How to treat SpA: choices and outcomes with bDMARDs”

Quels biomédicaments après échec d’un anti-TNF?

- OP0237 Interleukin-17 or TNF blockade in patients with axial spondyloarthritis after withdrawal of at least one TNF inhibitor – Adrian Ciurea et al.
  - Vendredi 14 juin
  - 11 h 10 – Hall 7A – Abstract session “How to treat SpA: choices and outcomes with bDMARDs”

Impacts des MEA sur le choix d’un anti-TNF

- OP0233 The impact of extra-articular manifestations on the choice of TNF inhibitor in patients with axial spondyloarthritis in the BSRBR-AS register – Mohammad H. Derakhshan et al.
  - Vendredi 14 juin
  - 11 h 30 – Hall 7A – Abstract session “How to treat SpA: choices and outcomes with bDMARDs”

Place de l’IRM dans le diagnostic

- OP0344 Which magnetic resonance imaging lesions of the sacroiliac joints are of diagnostic value for axial spondyloarthritis? – Xenofon Baraliakos et al.
  - Samedi 15 juin
  - 13 h 15 – Hall 7B – Clinical science session “To image or not to image in spondyloarthritis?”
Maladies auto-immunes
— La sélection du Pr Christophe Richez (Bordeaux)

Lupus

Outils diagnostiques et pronostiques

- **OP0020 Less is more: analysing the impact of repeated antinuclear antibody testing** — Ai Li Yeo et al.
  - Mercredi 12 juin
  - 17 h 05 – Hall 6 – “Opening plenary abstract session”

- **OP0128 Systemic lupus erythematosus disease characteristics associated with the type I interferon gene signature: baseline data of the SLE prospective observational cohort study (SPOCS)** — Richard Furie et al.
  - Jeudi 13 juin
  - 11 h 00 – Hall 7B – Abstract session “SLE, Sjögren and APS: systemic autoimmunity in the real life”

Traitements

- **OP0042 Long-term effects of synergetic B cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory SLE: two year results** — Y.K. Onno et al.
  - Mercredi 12 juin
  - 16 h 50 – Hall 7B – Abstract session “SLE, Sjögren’s and APS – Treatment”

- **OP0043 Withdrawal of a low dose (5 mg) of corticosteroids in systemic lupus in remission for more than a year is at risk of relapse – The CORTICOLUP trial** — Alexis Mathian et al.
  - Mercredi 12 juin
  - 17 h 00 – Hall 7B – Abstract session “SLE, Sjögren’s and APS – Treatment”

- **OP0247 Effect of immunosuppressive drug withdrawal on damage progression and flare occurrence in SLE patients in remission** — Margherita Zen et al.
  - Vendredi 14 juin
  - 10 h 30 – Salle N103/N104 – Abstract session “SLE news”

Syndrome de Gougerot-Sjögren

Outils pronostiques

- **OP0126 Lymphoma arising at the time of diagnosis of primary Sjögren syndrome: a highly-active systemic subset of the disease** — Soledad Retamozo et al.
  - Jeudi 13 juin
  - 10 h 40 – Hall 7B – Abstract session “SLE, Sjögren and APS: systemic autoimmunity in the real life”

Traitements

- **OP0039 Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a randomised placebo-controlled phase III trial** — Alan Baer et al.
  - Mercredi 12 juin
  - 16 h 20 – Hall 7B – Abstract session “SLE, Sjögren’s and APS – Treatment”

- **OP0045 Abatacept treatment of patients with early active primary Sjögren’s syndrome – A randomized, double-blind placebo-controlled phase III-study (ASAP-III)** — Hendrika Bootsmma et al.
  - Mercredi 12 juin
  - 17 h 20 – Hall 7B – Abstract session “SLE, Sjögren’s and APS – Treatment”

- **OP0202 Effect of RSLV-132 on fatigue in patients with primary Sjögren's syndrome – Results of a phase II randomised, double-blind, placebo-controlled, proof of concept study** — Wan-fai Ng et al.
  - Jeudi 13 juin
  - 14 h 45 – Salle N103/104 – Clinical Science session “My joints hurt and I’m overwhelmingly tired – Fatigue in rheumatoid arthritis”
Maladies auto-immunes
— La sélection du Pr Christophe Richez (Bordeaux)

**Sclérodermie**

*Outils pronostiques*

- **OP0065 The very early diagnosis of systemic sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study** – Silvia Bellando Randone et al.
  - Mercredi 12 juin
  - 16 h 50 – Salle N101/N102 – Abstract session "Myositis and SSc: clinical highlights 2019"

*Traitements*

- **OP0017 Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial** – Oliver Distler et al.
  - Mercredi 12 juin
  - 16 h 35 – Hall 6 – “Opening plenary abstract session”

  - Vendredi 14 juin
  - 10 h 50 – Hall 7B – Abstract session “SSc and myositis – Novel therapeutic options”

- **OP0243 Efficacy of pirfenidone in systemic sclerosis related interstitial lung disease – A randomised controlled trial** – Nupoor Acharya et al.
  - Vendredi 14 juin
  - 11 h 00 – Hall 7B – Abstract session “SSc and myositis – Novel therapeutic options”

- **OP0327 Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial** – Anna-Maria Hoffmann-Vold et al.
  - Vendredi 14 juin
  - 16 h 50 – South auditorium – Basic and Translational science session “The future of therapeutic strategies”

**Myosite**

- **OP0244 Efficacy and safety of low-dose IL-2 in patients with multiple myositis/dermatomyositis** – Sheng-Xiao Zhang et al.
  - Vendredi 14 juin
  - 11 h 10 – Hall 7B – Abstract session “SSc and myositis – Novel therapeutic options”
Maladies auto-immunes

— La sélection du Pr Christophe Richez (Bordeaux)

Vascularite

Traitements

  - Jeudi 13 juin
  - 10 h 20 – South auditorium – Abstract session “Vasculitis”

- **OP0141 CD28 as a potential therapeutic target for giant cell arteritis** – Ryu Watanabe et al.
  - Jeudi 13 juin
  - 10 h 30 – South auditorium – Abstract session “Vasculitis”

- **OP0147 KAWAKINRA: a phase IIA multicenter trial to assess the efficacy, and safety of anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease** – Isabelle Koné-Paut et al.
  - Jeudi 13 juin
  - 11 h 30 – South auditorium – Abstract session “Vasculitis”

- **OP0339 Tocilizumab in giant cell arteritis. Monotherapy versus combined with conventional immunosuppressive drugs** – Monica Calderón-Goercke et al.
  - Samedi 15 juin
  - 10 h 15 – Salle N111/112 – Clinical Science session “Current treatment of vasculitis”

Complications auto-immunes des inhibiteurs de checkpoint

- **OP0165 EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy** – Marie Kostine et al.
  - Jeudi 13 juin
  - 10 h 40 – Salle N111/N112 – Abstract session “Other orphan diseases”
<table>
<thead>
<tr>
<th>Thématique</th>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spondyloarthrite</td>
<td>14 h 51</td>
<td>Salle N103/N104</td>
<td>OP0005 Incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>15 h 15</td>
<td>Salle N103/N104</td>
<td>OP0007 High body mass index (BMI) in psoriatic arthritis (PsA) is associated with higher disease activity in joints and skin, impaired quality of life and more disability: results from the PsAbio study</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>15 h 27</td>
<td>Salle N103/N104</td>
<td>OP0008 Sustained low disease activity after weight loss treatment in patients with psoriatic arthritis and obesity; a 12-months follow-up</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 20</td>
<td>Hall 7B</td>
<td>OP0039 Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a randomised placebo-controlled phase III trial</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 25</td>
<td>Hall 6</td>
<td>LB0001 Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 35</td>
<td>Hall 8</td>
<td>OP0025 Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: phase 2 study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 35</td>
<td>Hall 6</td>
<td>OP0017 Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>16 h 45</td>
<td>Hall 7A</td>
<td>OP0034 Do smoking and socio-economic factors independently influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 50</td>
<td>Hall 7B</td>
<td>OP0042 Long-term effects of synergetic B cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory SLE: two year results</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 50</td>
<td>Salle N101/N102</td>
<td>OP0065 The very early diagnosis of systemic sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>17 h 00</td>
<td>Hall 7B</td>
<td>OP0043 Withdrawal of a low dose (5 mg) of corticosteroids in systemic lupus in remission for more than a year is at risk of relapse – The CORTICOLUP trial</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>17 h 05</td>
<td>Hall 6</td>
<td>OP0020 Less is more: analysing the impact of repeated antinuclear antibody testing</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>17 h 20</td>
<td>Hall 7B</td>
<td>OP0045 Abatacept treatment of patients with early active primary Sjögren’s syndrome – A randomized, double-blind placebo-controlled phase III-study (ASAP-III)</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>17 h 25</td>
<td>Hall 8</td>
<td>OP0030 Randomized controlled 24-week trial evaluating the safety and efficacy of blinded tapering versus continuation of long-term prednisone (5 mg/d) in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>17 h 30</td>
<td>Salle N107/N108</td>
<td>OP0095 Influence of periodontitis on disease activity, physical function, and safety in patients with rheumatoid arthritis: an observational study using the IORRA cohort</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>17 h 35</td>
<td>Hall 6</td>
<td>LB0002 Randomised, double-blind, placebo-controlled, multiple-dose, phase 2B study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23P19 monoclonal antibody, in patients with active psoriatic arthritis</td>
</tr>
</tbody>
</table>

Votre parcours clé en main

Cliquez sur chaque abstract pour accéder à sa page
<table>
<thead>
<tr>
<th>Thématique</th>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spondyloarthrite</td>
<td>10 h 20</td>
<td>Hall 8</td>
<td>OP0108 Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active PsA: overall and TNF-inhibitor-naïve population results from a 48-week phase 2B randomised study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10 h 20</td>
<td>South auditorium</td>
<td>OP0140 Long-term outcome of tocilizumab for patients with giant cell arteritis: results from part 2 of the GiACTA trial</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10 h 30</td>
<td>Hall 8</td>
<td>OP0109 Efficacy of filgotinib vs placebo in active psoriatic arthritis: patient-level data from equator, a randomized, phase 2 study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10 h 30</td>
<td>South auditorium</td>
<td>OP0141 CD28 as a potential therapeutic target for giant cell arteritis</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10 h 40</td>
<td>Hall 8</td>
<td>OP0110 Ixekizumab improves signs and symptoms of psoriatic arthritis in patients who have had inadequate response to 1 or 2 tumor necrosis factor inhibitors</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10 h 40</td>
<td>Hall 7B</td>
<td>OP0126 Lymphoma arising at the time of diagnosis of primary Sjögren syndrome: a highly-active systemic subset of the disease</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10 h 40</td>
<td>Salle N111/N112</td>
<td>OP0165 EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10 h 50</td>
<td>Hall 7A</td>
<td>OP0119 The pre-treatment gut microbiome predicts early response to rheumatoid arthritis therapy</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10 h 50</td>
<td>Hall 8</td>
<td>OP0111 A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combination for treating psoriatic arthritis: a comparison of the composite measures used to evaluate disease activity</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11 h 00</td>
<td>Hall 7B</td>
<td>OP0128 Systemic lupus erythematosus disease characteristics associated with the type I interferon gene signature: baseline data of the SLE prospective observational cohort study (SPOCS)</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>11 h 30</td>
<td>Hall 8</td>
<td>OP0115 General and sex-specific predictors of PsA among patients with psoriasis</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11 h 30</td>
<td>South auditorium</td>
<td>OP0147 KAWAKINRA: a phase IIa multicenter trial to assess the efficacy, and safety of anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>14 h 45</td>
<td>Salle N103/104</td>
<td>OP0202 Effect of RSLV-132 on fatigue in patients with primary Sjögren’s syndrome – Results of a phase II randomised, double-blind, placebo-controlled, proof of concept study</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>15 h 35</td>
<td>Hall 6</td>
<td>Interstitial lung disease and best management in rheumatic disease</td>
</tr>
</tbody>
</table>
## Thématique

### Polyarthrite rhumatoïde

<table>
<thead>
<tr>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 h 20</td>
<td>Hall 8</td>
<td>OP0223 Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in MTX-IR patients with rheumatoid arthritis</td>
</tr>
<tr>
<td>10 h 30</td>
<td>Hall 8</td>
<td>OP0224 Results of a phase 2 study of RG6125, an anti-cadherin-11 monoclonal antibody, in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy</td>
</tr>
</tbody>
</table>

### Spondyloarthrite

<table>
<thead>
<tr>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 h 20</td>
<td>Hall 7A</td>
<td>OP0231 Dual neutralisation of IL-17A and IL-17F with bimekizumab was associated with improvements in patient-reported and quality-of-life outcomes in patients with active ankylosing spondylitis: results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study</td>
</tr>
<tr>
<td>10 h 40</td>
<td>Hall 7A</td>
<td>OP0234 Efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study</td>
</tr>
</tbody>
</table>

### Maladies auto-immunes

<table>
<thead>
<tr>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 h 30</td>
<td>Salle N103/N104</td>
<td>OP0247 Effect of immunosuppressive drug withdrawal on damage progression and flare occurrence in SLE patients in remission</td>
</tr>
<tr>
<td>10 h 50</td>
<td>Hall 7B</td>
<td>OP0242 Safety profile of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>11 h 00</td>
<td>Hall 7B</td>
<td>OP0243 Efficacy of pirfenidone in systemic sclerosis related interstitial lung disease – A randomised controlled trial</td>
</tr>
<tr>
<td>11 h 10</td>
<td>Hall 8</td>
<td>OP0228 GSK3196165 an investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis (RA)</td>
</tr>
<tr>
<td>11 h 10</td>
<td>Hall 7B</td>
<td>OP0244 Efficacy and safety of low-dose IL-2 in patients with multiple myositis/dermatomyositis</td>
</tr>
<tr>
<td>11 h 30</td>
<td>Hall 7A</td>
<td>OP0233 The impact of extra-articular manifestations on the choice of TNF inhibitor in patients with axial spondyloarthritis in the BSRBR-AS register</td>
</tr>
</tbody>
</table>

### Maladies auto-immunes

<table>
<thead>
<tr>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 h 50</td>
<td>South auditorium</td>
<td>OP0327 Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial</td>
</tr>
</tbody>
</table>

---

*Le parcours d’or*
### SAMEDI 15 JUIN

<table>
<thead>
<tr>
<th>Thématique</th>
<th>Horaires</th>
<th>Lieu</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>8 h 06</td>
<td>Hall 7B</td>
<td>LB0004 Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily + methotrexate: a randomised non-inferiority phase 3B/4 study</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>8 h 12</td>
<td>Hall 7B</td>
<td>LB0005 Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biologic disease-modifying anti-rheumatic drugs: 24-week results</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>8 h 36</td>
<td>Hall 7B</td>
<td>LB0009 First-in-human study of novel implanted vagus nerve stimulation device to treat rheumatoid arthritis</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>8 h 42</td>
<td>Hall 7B</td>
<td>LB0010 Ultra-low doses of rituximab for retreatment of rheumatoid arthritis: a randomised controlled non-inferiority trial</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10 h 15</td>
<td>Salle N111/112</td>
<td>OP0339 Tocilizumab in giant cell arteritis. Monotherapy versus combined with conventional immunosuppressive drugs</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>13 h 05</td>
<td>Salle N101/N102</td>
<td>OP0345 Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved a sustained DMARD-free status</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>13 h 15</td>
<td>Hall 7B</td>
<td>OP0344 Which magnetic resonance imaging lesions of the sacroiliac joints are of diagnostic value for axial spondyloarthritis?</td>
</tr>
</tbody>
</table>
Retrouvez en vidéo chaque thématique et sélection commentées par les experts

Et retrouvez l’intégralité de l’émission spéciale sur
→ www.edimark.fr/EULAR/2019/ESP